The present invention provides a scaffold for culturing retinal tissue comprising an amount of gelatin, an amount of chondroitin sulfate, an amount of hyaluronic acid, wherein the amount of gelatin, chondroitin sulfate, and hyaluronic acid are prepared into a three-dimensional monolith, wherein the monolith is sectioned into planar sheets, and an amount of laminin-521.

An implantable medical device and methods for making and using the same are provided. In various embodiments, the device comprises a central hub structure in communication with at least one housing or pod capable of containing cells and therapeutic materials. Also provided are membrane structures and methods of forming the same, the membranes comprising a gradient of varying porosity for use with devices of the present disclosure, as well as other uses.

The present disclosure provides an encapsulated liver tissue that can be used in vivo to improve liver functions, in vitro to determine the hepatic metabolism and/or hepatotoxicity of an agent and ex vivo to remove toxic compounds from patients' biological fluid. The encapsulated liver tissue comprises at least one liver organoid at least partially covered with a biocompatible cross-linked polymer. Processes for making the encapsulated liver tissue are also provided.

A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.

Provided is a cell structure including: a connective tissue structure; and an epithelial structure placed on the connective tissue structure, in which the connective tissue structure contains a fragmented extracellular matrix component and first cells including mesenchymal cells, at least a part of the fragmented extracellular matrix component is placed between the first cells, and the epithelial structure contains epithelial cells.

Disclosed herein are synthetic hydrogel useful for the generation, storage and administration of cellular structures such as spheroids and organoids.

The present invention provides a method of constituting a tissue construct in vitro using a tissue without depending on scaffold materials. A method of integrating a biological tissue with a vascular system in vitro, comprising coculturing a biological tissue with vascular cells and mesenchymal cells. A biological tissue which has been integrated with a vascular system by the above-described method. A method of preparing a tissue or an organ, comprising transplanting the biological tissue described above into a non-human animal and differentiating the biological tissue into a tissue or an organ in which vascular networks have been constructed. A method of regeneration or function recovery of a tissue or an organ, comprising transplanting the biological tissue described above into a human or a non-human animal and differentiating the biological tissue into a tissue or an organ in which vascular networks have been constructed. A method of preparing a non-human chimeric animal, comprising transplanting the biological tissue described above into a non-human animal and differentiating the biological tissue into a tissue or organ in which vascular networks have been constructed. A method of evaluating a drug, comprising using at least one member selected from the group consisting of the biological tissue described above, the tissue or organ prepared by the method described above, and the non-human chimeric animal prepared by the method described above. A composition for regenerative medicine, comprising a biological tissue which has been integrated with a vascular system by the method described above.

The present disclosure provides engineered tissue constructs having a population of cells, such as hepatocytes and stromal cells, and methods of making and using the same (e.g., for treating a disease or disorder, such as acute liver failure, a urea cycle disorder, or hyperbilirubinemia (e.g., in a subject having Crigler-Najjar syndrome) in a human subject in need thereof).

The present invention relates to a tissue-engineered intervertebral disc (IVD) comprising a nucleus pulposus structure comprising a first population of living cells and an annulus fibrosis structure surrounding and in contact with the nucleus pulposus structure, the annulus fibrosis structure comprising a second population of living cells and collagen.

A biomaterial including a resorbable porous matrix formed from a material including collagen, and exhibiting an inner volume and an outer surface. Advantageously, the biomaterial includes at least one type of living biological cells of a tissue, disposed in the inner volume and alternatively or complementarily on the surface of the porous matrix. The biomaterial forms a tissue substitute being close to a native tissue, in particular in terms of biological structure present in the tissue, and physiological functions.